|
Date
|
Title
|
Sponsor
|
| 2006-present |
A Clinical trial of Ceftriaxone in Subjects with Amyotrophic Lateral Sclerosis |
National Institutes of Health |
| 2007-present |
Electrical Impedance Myography in ALS |
ALS Association |
| 2008-present |
ALS Biomarker Study |
ALS Association |
| 2009-present |
A Clinical Trial of Lithium and Riluzole in ALS |
National Institutes of Health |
| 2008-present |
CSF Indicators for Diagnosis and Disease Progression in ALS |
National Institutes of Health |
| 2009-present |
Early Events at the Neuromuscular Junction in ALS |
WFUHS Translational Science Institute |
| 2003-2007 |
A Multi-Center Study of Minocycline in ALS |
National Institutes of Health |
| 2006-2009 |
Ultrasound of peripheral nerves in ALS |
Muscular Dystrophy Association |
| 2006-2007 |
ALSRG Collection of Data and Biomaterial for Repository Banking to Facilitate Research into the Etiology of ALS and Related Motor Neuron Diseases |
National Institutes of Health |
| 1997-2000 |
Efficacy, Safety, Tolerability Study of SR57746A in Patients with Amyotrophic Lateral Sclerosis |
Sanofi Recherche |
| 2000-2002 |
A Clinical Trial of Topiramate in ALS |
Ortho-McNeil Pharmaceuticals |
| 2001-2003 |
Motor Neuron Trophic/Toxic Substances in Cerebrospinal Fluid and Serum in ALS Patients |
WFSM Intramural Research |
| 2001-2003 |
A Double-Blind, Controlled, Multicenter Phase 2/3 Study to Assess the Safety and Efficacy of AVP-923 in the Treatment of Pseudobulbar Affect in Patients with Amyotrophic Lateral Sclerosis |
Avanir Pharmaceuticals (99-AVR-102) |
| 2000-2003 |
A Clinical Trial of Creatine in ALS |
Muscular Dystrophy Association |
| 2003-2004 |
ALS and Hsp70: A Potential New Therapy |
WFSM Center for Investigative Neuroscience |
| 2003-2004 |
A Clinical Trial of Coenzyme Q10 in Patients with Amyotrophic Lateral Sclerosis (ALS) |
Muscular Dystrophy Association/Pharmacia |
| 2001-2005 |
A Clinical Trial of Celebrex in Subjects with Amyotrophic Lateral Sclerosis |
Muscular Dystrophy Association/Pharmacia/Pfizer |